|
ZBTB10 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.61369999988004E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.37069999999839E-05 |
| Normal-vs-Stage2 |
4.48100000000062E-05 |
| Normal-vs-Stage3 |
1.85332000000038E-05 |
| Normal-vs-Stage4 |
2.14849999999878E-05 |
| Stage1-vs-Stage2 |
2.913400E-01 |
| Stage1-vs-Stage3 |
5.437400E-01 |
| Stage1-vs-Stage4 |
3.042000E-01 |
| Stage2-vs-Stage3 |
5.559800E-01 |
| Stage2-vs-Stage4 |
9.540200E-01 |
| Stage3-vs-Stage4 |
5.804600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.41170000000912E-06 |
| Normal-vs-AfricanAmerican |
9.872400E-02 |
| Normal-vs-Asian |
1.241340E-04 |
| Caucasian-vs-AfricanAmerican |
1.740000E-01 |
| Caucasian-vs-Asian |
6.857400E-01 |
| AfricanAmerican-vs-Asian |
1.408420E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.56109999991128E-07 |
| Normal-vs-Female |
4.82560000003573E-06 |
| Male-vs-Female |
1.739820E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.950700E-04 |
| Normal-vs-Age(41-60Yrs) |
8.1818999997374E-07 |
| Normal-vs-Age(61-80Yrs) |
2.04699999994951E-06 |
| Normal-vs-Age(81-100Yrs) |
2.276100E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.937000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.626020E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.374200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.235000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.065400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.086800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.681200E-01 |
| Classical-VS-Follicular |
3.586800E-04 |
| Classical-VS-Other |
1.522030E-01 |
| Classical-VS-Normal |
2.567700E-04 |
| Tall-VS-Follicular |
2.253200E-01 |
| Tall-VS-Other |
3.122000E-01 |
| Tall-VS-Normal |
2.410500E-04 |
| Follicular-VS-Other |
7.802600E-01 |
| Follicular-VS-Normal |
1.25569999953612E-08 |
| Other-VS-Normal |
7.378200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.69180000009206E-08 |
| Normal-vs-N1 |
4.015000E-04 |
| N0-vs-N1 |
4.689000E-01 |
|
|
